Series date: 
01/01/2023 - 7:30am to 12/31/2023 - 7:30am

DESCRIPTION
This series is held weekly on Friday, 7:30 - 8:30 a.m.

Consultants, fellows and visiting professors present a 45 minute discussion topic which is intended to be a comprehensive review after which there is a 10-15 minute period for questions.  These "state-of-the-art" lectures are directed at the faculty and fellow level.  

TARGET AUDIENCE
The audience is primarily the physicians in our division, but all members of the division, i.e. nurses, NP/PAs and allied health staff are encouraged to attend.  Other areas/divisions are allowed to attend if they wish.  

LEARNING OBJECTIVES
Upon conclusion of this program, participants should be able to:

  • Describe how to apply clinical practice updates to improve patient outcomes.

  • Critically review clinical and basic research literature using an evidence-based approach.

  • Debate if specific findings are relevant and applicable to patient care.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Statement(s): 
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies: 
Hatem Amer, M.D. - Grant/Research Support - Kaneka Pharma
 
All relevant financial relationships listed for these individuals have been mitigated.

No relevant financial relationship(s) with ineligible companies: 
Iasmina M. Craici, M.D.; Ladan Zand, M.D.; Melissa L. Hanson, Jacqlyn (Jackie) A. Oakland, Kathy Hegna Zelinske
 
References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here. 

ATTENDANCE/CREDIT
Text the session code (provided only at the session) to 507-200-3010image within 48 hours of the live presentation to record attendance.  All learners are encouraged to text attendance regardless of credit needs.  This number is only used for receiving text messages related to tracking attendance.  Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows. 

TRANSCRIPT
Any credit or attendance awarded from this series will appear on your Transcript.

COURSE DIRECTORS
Ladan Zand, M.D. and Iasmina Craici, M.D.

QUESTIONS?
Contact Kathy Hegna Zelinske at phone 6-1044 OR Jacqlyn Oakland at phone 4-3479

*Required Information for Accreditation is posted in Outlook Calendar Invitation.
Support location: 
Minnesota

Sessions

Session Date
Nephrology Hypertension Journal Club Aprocitentan for Resistant Hypertension: The PRECISION Trial - January 6, 2023 01/06/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Temporal Trends of Dietary Risk Factors after a Diagnosis of Kidney Stones: January 13, 2023 01/13/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Myeloid CCR2 Promotes Atherosclerosis After AKI: January 20, 2023 01/20/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Five Year Symptom Trajectories in Nondialysis, Dependent CKD Patients: January 27, 2023 01/27/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Results from Part A of the multi center, double blind, randomized, placebo controlled NeflgArd trial, which evaluated targeted release formulation of budesonide for treatment of primary immunoglobulin A nephropathy 02/03/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) A Novel Method for Estimating Right Atrial Pressure with Point-of-Care Ultrasound February 24, 2023 02/24/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Menstrual Abnormalities and Reproductive Lifespan in Females with CKD : March 3, 2023 03/03/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Upregulated PD-Q signaling antagonized glomerular health in aged kidneys and disease March 10, 2023 03/10/2023 - 7:30am to 8:30am
***Session CANCELLED***(Nephrology Hypertension Journal Club) Optimized Immunosuppression to Prevent Graft Failute in Renal Transplant Recipients with HLA Antibodies : March 24, 2023 03/24/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Effectiveness of Mycophenolate Mofetil Among Patients with Progressive IgA Nephropathy March 31, 2023 03/31/2023 - 7:30am to 8:30am

Pages